These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 27357277)

  • 1. Update on Current Evidence for Hepatitis C Therapeutic Options in HCV Mono-infected Patients.
    Hull MW; Yoshida EM; Montaner JS
    Curr Infect Dis Rep; 2016 Jul; 18(7):22. PubMed ID: 27357277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Grazoprevir/elbasvir combination therapy for HCV infection.
    Vallet-Pichard A; Pol S
    Therap Adv Gastroenterol; 2017 Jan; 10(1):155-167. PubMed ID: 28286567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C Virus Resistance Testing in Genotype 1: The Changing Role in Clinical Utility.
    Molino S; Martin MT
    Ann Pharmacother; 2017 Sep; 51(9):811-816. PubMed ID: 28480743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct Acting Anti-hepatitis C Virus Drugs: Clinical Pharmacology and Future Direction.
    Geddawy A; Ibrahim YF; Elbahie NM; Ibrahim MA
    J Transl Int Med; 2017 Mar; 5(1):8-17. PubMed ID: 28680834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adding ribavirin to newer DAA regimens does not affect SVR rates in HCV genotype 1 infected persons: results from ERCHIVES.
    Butt AA; Yan P; Marks K; Shaikh OS; Sherman KE;
    Aliment Pharmacol Ther; 2016 Oct; 44(7):728-37. PubMed ID: 27459341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of hepatitis C: Results in real life.
    Hézode C
    Liver Int; 2018 Feb; 38 Suppl 1():21-27. PubMed ID: 29427481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal IFN-free therapy in treatment-naïve patients with HCV genotype 1 infection.
    Asselah T; Marcellin P
    Liver Int; 2015 Jan; 35 Suppl 1():56-64. PubMed ID: 25529088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Robust HCV Genotype 3a Infectious Cell Culture System Permits Identification of Escape Variants With Resistance to Sofosbuvir.
    Ramirez S; Mikkelsen LS; Gottwein JM; Bukh J
    Gastroenterology; 2016 Nov; 151(5):973-985.e2. PubMed ID: 27453546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of the Best Direct-Acting Antiviral Regimen for Patients With Hepatitis C Virus Genotype 3 Infection: A Systematic Review and Network Meta-analysis.
    Berden FA; Aaldering BR; Groenewoud H; IntHout J; Kievit W; Drenth JP
    Clin Gastroenterol Hepatol; 2017 Mar; 15(3):349-359. PubMed ID: 27840182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiretroviral Use in the CEASE Cohort Study and Implications for Direct-Acting Antiviral Therapy in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection.
    Martinello M; Dore GJ; Skurowski J; Bopage RI; Finlayson R; Baker D; Bloch M; Matthews GV
    Open Forum Infect Dis; 2016 Apr; 3(2):ofw105. PubMed ID: 27419177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C treatment from "response-guided" to "resource-guided" therapy in the transition era from interferon-containing to interferon-free regimens.
    Yu ML
    J Gastroenterol Hepatol; 2017 Aug; 32(8):1436-1442. PubMed ID: 28124463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3.
    Belperio PS; Shahoumian TA; Loomis TP; Mole LA; Backus LI
    J Hepatol; 2019 Jan; 70(1):15-23. PubMed ID: 30266283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacological interactions between direct-acting antivirals for the treatment of chronic hepatitis c and psychotropic drugs.
    Roncero C; Villegas JL; Martínez-Rebollar M; Buti M
    Expert Rev Clin Pharmacol; 2018 Oct; 11(10):999-1030. PubMed ID: 30199279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis.
    Majumdar A; Kitson MT; Roberts SK
    Aliment Pharmacol Ther; 2016 Jun; 43(12):1276-92. PubMed ID: 27087015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High rates of hepatitis C virus (HCV) cure using direct-acting antivirals in HIV/HCV-coinfected patients: a real-world perspective.
    Hawkins C; Grant J; Ammerman LR; Palella F; Mclaughlin M; Green R; Mcgregor D; Stosor V
    J Antimicrob Chemother; 2016 Sep; 71(9):2642-5. PubMed ID: 27330060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-free, direct-acting antiviral therapy for chronic hepatitis C.
    Gutierrez JA; Lawitz EJ; Poordad F
    J Viral Hepat; 2015 Nov; 22(11):861-70. PubMed ID: 26083155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Drug-Drug Interaction Potential of Antiviral Agents for the Treatment of Chronic Hepatitis C Infection.
    Garrison KL; German P; Mogalian E; Mathias A
    Drug Metab Dispos; 2018 Aug; 46(8):1212-1225. PubMed ID: 29695614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy.
    Milazzo L; Lai A; Calvi E; Ronzi P; Micheli V; Binda F; Ridolfo AL; Gervasoni C; Galli M; Antinori S; Sollima S
    HIV Med; 2017 Apr; 18(4):284-291. PubMed ID: 27477612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: Results from the multicenter German hepatitis C cohort (GECCO-03).
    Wehmeyer MH; Ingiliz P; Christensen S; Hueppe D; Lutz T; Simon KG; Schewe K; Boesecke C; Baumgarten A; Busch H; Rockstroh J; Schmutz G; Kimhofer T; Berger F; Mauss S; Schulze Zur Wiesch J
    J Med Virol; 2018 Feb; 90(2):304-312. PubMed ID: 28710853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic Advances in HCV Genotype 1 Infection: Insights from the Society of Infectious Diseases Pharmacists.
    Deming P; Martin MT; Chan J; Dilworth TJ; El-Lababidi R; Love BL; Mohammad RA; Nguyen A; Spooner LM; Wortman SB
    Pharmacotherapy; 2016 Feb; 36(2):203-17. PubMed ID: 26846728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.